Javascript must be enabled to continue!
DESIGN AND EVALUATION OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR DEFERASIROX
View through CrossRef
In order to increase deferasirox’s (DEF) solubility and dissolution rate, the study aims to develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS). The impact of concentrations of oil and surfactant on emulsification and in vitro drug release was investigated using an oil, surfactant and cosurfactant mixture. Based on a minimum time of emulsification and a high cumulative percentage of drug dissolution, the formulation F6 was optimized. The optimized formulation showed an emulsification efficiency of 19 ± 0.67 seconds and in vitro drug release of 98.65 ± 0.259 % in 30 minutes. Neusilin® US2 was used to solidify the formulation, which has a high oil adsorption capacity and better micromeritic characters. The analyses of X-ray powder diffraction and differential scanning calorimetry studies displayed the transformation of DEF from its crystalline form to an amorphous form. So, this study demonstrates that the S-SNEDDS is a viable innovative drug delivery strategy for elevating DEF’s solubility and dissolution rate.
Title: DESIGN AND EVALUATION OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR DEFERASIROX
Description:
In order to increase deferasirox’s (DEF) solubility and dissolution rate, the study aims to develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS).
The impact of concentrations of oil and surfactant on emulsification and in vitro drug release was investigated using an oil, surfactant and cosurfactant mixture.
Based on a minimum time of emulsification and a high cumulative percentage of drug dissolution, the formulation F6 was optimized.
The optimized formulation showed an emulsification efficiency of 19 ± 0.
67 seconds and in vitro drug release of 98.
65 ± 0.
259 % in 30 minutes.
Neusilin® US2 was used to solidify the formulation, which has a high oil adsorption capacity and better micromeritic characters.
The analyses of X-ray powder diffraction and differential scanning calorimetry studies displayed the transformation of DEF from its crystalline form to an amorphous form.
So, this study demonstrates that the S-SNEDDS is a viable innovative drug delivery strategy for elevating DEF’s solubility and dissolution rate.
Related Results
Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major
Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major
Abstract
Abstract 5294
Background:
Deferasirox is a relatively new once-daily oral iron chelator widely used for ...
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
This study aims to solidify the self-nanoemulsifying drug delivery system with rosuvastatin (SNEDDS Ros) for application in solid dosage forms. The liquid SNEDDS Ros system is soli...
Protective Effects of Vitamin C Concomitant Treatment on Deferasirox-induced Renal Toxicity in Rats
Protective Effects of Vitamin C Concomitant Treatment on Deferasirox-induced Renal Toxicity in Rats
Background and Aim: Deferasirox (Exjade) is an iron-chelating drug used in patients with beta-thalassemia major. Oxidative stress is among f the major causes of nephrotoxicity and ...
Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia
Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia
Background: Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Abstract 5608: Iron depletion by deferasirox have a synergistic effect on sorafenib in hepatocellular carcinoma.
Abstract 5608: Iron depletion by deferasirox have a synergistic effect on sorafenib in hepatocellular carcinoma.
Abstract
Purpose. Sorafenib is a multiple kinase inhibitor approved for advanced hepatocellular carcinoma(HCC). However, we couldn't get sufficient effect in clinica...
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Abstract
Abstract 3424
Patients with aplastic anemia (AA) are suffered from various complications related to bone marrow failure and peripheral cytope...
Evaluating Effectiveness of Deferasirox Versus Deferoxamine in Improving Clinical Outcomes among Patients with Transfusion-Dependent Thalassemia: A Randomized Controlled Trial
Evaluating Effectiveness of Deferasirox Versus Deferoxamine in Improving Clinical Outcomes among Patients with Transfusion-Dependent Thalassemia: A Randomized Controlled Trial
Background: Transfusion-dependent β-thalassemia necessitates lifelong blood transfusions that progressively accumulate systemic iron, causing cardiomyopathy, hepatic cirrhosis, and...

